Clinical Trials Directory

Trials / Completed

CompletedNCT03731741

Does Oral Pentoxifylline Administration Improve Hemoglobin in Hemodialysis Patients?

Effect of Pentoxifylline Administration on Hemoglobin Level of Hemodialysis Patients

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
57 (actual)
Sponsor
Tanta University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Our study investigated the effect of using a known drug used in intermittent claudication (named pentoxifylline) as an adjuvant to erythropoietin stimulating agents to improve anemia of hemodialysis patients.

Detailed description

Fifty out of 57 hemodialysis anemic patients were finally included. They were assigned to two groups of equal numbers. Oral Pentoxifylline 400mg once daily was added to the treatment group which was compared to the control group over a six months period regarding hemoglobin, hematocrit, serum albumin and CRP. Inclusion criteria: (Patients with ESRD on HD who have hemoglobin \<11 g/dl, taking Erythropoietin alfa 4000 -12000 I.U/wk and having a urea reduction ratio \>65%.). There were 57 patients who met the inclusion criteria out of 158 patients. Exclusion criteria: Iron deficiency anemia with transferrin saturation \<30%, intact PTH\>300pg/ml, vitamin B12 or folate deficiency (evidenced by macrocytosis), history of intolerance to pentoxifylline or other xanthine derivatives, recent retinal or cerebral hemorrhage or active peptic ulcer disease, pregnancy or breastfeeding, presence of systemic hematological disease or known hemoglobinopathy, major surgery, infection, acute myocardial infarction, or malignancy within the last three months and patients who refused to participate in the study.

Conditions

Interventions

TypeNameDescription
DRUGPentoxifyllinea known drug of xanthine derivatives used in intermittent claudication

Timeline

Start date
2017-11-01
Primary completion
2018-05-03
Completion
2018-05-04
First posted
2018-11-06
Last updated
2018-11-08

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT03731741. Inclusion in this directory is not an endorsement.